The Efficacy of Levosimendan Combined With Tolvaptan in the Treatment of Patients With Acute Decompensated Heart Failure
Objective To explore the clinical value of levocimentan and tolvaptan in the treatment of acute decompensated heart failure.Methods A total of 56 patients with acute decompensated heart failure who received treatment in Beijing Hospital of Integrated Traditional Chinese and Western Medicine from June 2021 to August 2023 were selected,and divided into groups according to the treatment differences of the study subjects.The control group receiving conventional treatment was set up,while the study group receiving levoximandan combined with torvastan was set up,with 28 cases in each group.The therapeutic effect,serum related indexes,cardiac function indexes and adverse reactions were compared between the two groups.Results After treatment,the efficacy of the study group(96.43％)was higher than that of the control group(78.57％)(χ2=4.082,P=0.043).After treatment,the values of serum procalcitonin,N-terminal brain natriuretic peptide precursor,interleukin-6 and hypersensitive C-reactive protein,left ventricular end-diastolic diameter and left ventricular end-systolic diameter in the study group were lower than those in the control group,but the values of left ventricular ejection fraction were higher than those in the control group(P<0.05).The adverse reaction rate of the study group was 3.57％lower than that of the control group(28.57％)(χ2=4.766,P=0.029).Conclusion The combination of levosimendan and tolvaptan in acute decompensated heart failure can significantly improve the hemodynamic status and cardiac function,so as to promote the relief of clinical symptoms.Moreover,both of these drugs have high safety and further clinical research is warranted.
NETL
NSTL
万方数据
